Recomendaciones para la prevención de la infección por virus respiratorio sincitial
- 1 October 2005
- journal article
- abstracts
- Published by Elsevier in Anales de Pediatría
- Vol. 63 (4) , 357-362
- https://doi.org/10.1157/13079818
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Palivizumab Use in Very Premature Infants in the Neonatal Intensive Care UnitPublished by American Academy of Pediatrics (AAP) ,2004
- Anti-Respiratory Syncytial Virus (RSV) Neutralizing Antibody Decreases Lung Inflammation, Airway Obstruction, and Airway Hyperresponsiveness in a Murine RSV ModelAntimicrobial Agents and Chemotherapy, 2004
- PalivizumabPediatric Drugs, 2004
- Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus InfectionsPediatrics, 2003
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003
- Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: Results from the palivizumab outcomes registryPediatric Pulmonology, 2003
- Reported Adverse Drug Events in Infants and Children Under 2 Years of AgePublished by American Academy of Pediatrics (AAP) ,2002
- Cost‐effectiveness of palivizumab in New ZealandJournal of Paediatrics and Child Health, 2002
- Respiratory syncytial virus infectionThe Lancet, 1999
- Respiratory syncytial virus: a community problem.BMJ, 1979